JAE LEE: Open Payments
NPI 1073776985 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$969 in 32 payments from 14 companies in 2025. Trend: 2023 $755 · 2024 $620 · 2025 $969
Food & beverage: $969
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 9 | $371 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $125 |
| Ipsen Biopharmaceuticals, Inc | 5 | $118 |
| Gilead Sciences, Inc. | 1 | $103 |
| Aimmune Therapeutics, Inc. | 1 | $35 |
| Novo Nordisk Inc | 2 | $35 |
| ABBVIE INC. | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Ardelyx, Inc. | 1 | $25 |
| Exact Sciences Corporation | 1 | $23 |
Products named: REZDIFFRA, IQIRVO, Livdelzi, EOHILIA, ENTYVIO, VOWST, Wegovy, TERLIVAZ.
Industry payments across MD — which companies pay providers there.
